Biren Amin
Stock Analyst at Piper Sandler
(1.14)
# 3,376
Out of 4,814 analysts
57
Total ratings
35.29%
Success rate
-18.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $182 → $110 | $56.02 | +96.36% | 6 | Apr 21, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $38 → $51 | $24.08 | +111.79% | 1 | Apr 14, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $38 | $12.28 | +209.45% | 1 | Mar 31, 2025 | |
| ELEV Elevation Oncology | Downgrades: Neutral | $10 → $0.7 | $0.38 | +82.29% | 2 | Mar 21, 2025 | |
| MNPR Monopar Therapeutics | Assumes: Overweight | $76 | $43.50 | +74.71% | 1 | Mar 19, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | $12 | $1.87 | +541.71% | 1 | Feb 19, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $74 → $71 | $24.32 | +191.94% | 2 | Feb 6, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Neutral | $34 → $4 | $4.65 | -13.98% | 3 | Jan 30, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Overweight | $35 | $6.47 | +440.96% | 1 | Dec 2, 2024 | |
| IMNM Immunome | Maintains: Overweight | $23 → $21 | $8.13 | +158.30% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $9 | $1.49 | +504.03% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $61.07 | +88.31% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $17.81 | +79.67% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $46 | $34.00 | +35.29% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $2.47 | +21.46% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $3.15 | +534.92% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $7.72 | +94.30% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.40 | +4,900.00% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.31 | +16,188.73% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.29 | +948.03% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $1.56 | +2,079.49% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $3.19 | +15,573.98% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $4.23 | +231.36% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $575.12 | +20.15% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $0.75 | +1,233.87% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.14 | - | 4 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $21.00 | +380.95% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $101.18 | -31.80% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $484.71 | -68.02% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $1.66 | +8,092.77% | 4 | Mar 6, 2017 |
Sarepta Therapeutics
Apr 21, 2025
Maintains: Overweight
Price Target: $182 → $110
Current: $56.02
Upside: +96.36%
LENZ Therapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $38 → $51
Current: $24.08
Upside: +111.79%
Centessa Pharmaceuticals
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $12.28
Upside: +209.45%
Elevation Oncology
Mar 21, 2025
Downgrades: Neutral
Price Target: $10 → $0.7
Current: $0.38
Upside: +82.29%
Monopar Therapeutics
Mar 19, 2025
Assumes: Overweight
Price Target: $76
Current: $43.50
Upside: +74.71%
Compass Therapeutics
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $1.87
Upside: +541.71%
Viking Therapeutics
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $24.32
Upside: +191.94%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Neutral
Price Target: $34 → $4
Current: $4.65
Upside: -13.98%
Corbus Pharmaceuticals Holdings
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $6.47
Upside: +440.96%
Immunome
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $8.13
Upside: +158.30%
Nov 14, 2024
Maintains: Overweight
Price Target: $11 → $9
Current: $1.49
Upside: +504.03%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $61.07
Upside: +88.31%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $17.81
Upside: +79.67%
Sep 4, 2024
Initiates: Overweight
Price Target: $46
Current: $34.00
Upside: +35.29%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $2.47
Upside: +21.46%
Jun 21, 2024
Reiterates: Overweight
Price Target: $20
Current: $3.15
Upside: +534.92%
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $7.72
Upside: +94.30%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.40
Upside: +4,900.00%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.31
Upside: +16,188.73%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $2.29
Upside: +948.03%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $1.56
Upside: +2,079.49%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $3.19
Upside: +15,573.98%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $4.23
Upside: +231.36%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $575.12
Upside: +20.15%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $0.75
Upside: +1,233.87%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $4.14
Upside: -
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $21.00
Upside: +380.95%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $101.18
Upside: -31.80%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $484.71
Upside: -68.02%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $1.66
Upside: +8,092.77%